|Awarded On||February 16, 2022|
|Title||Recruitment of First-Time, Tenure-Track Faculty Members|
|Award Mechanism||Recruitment of First-Time, Tenure-Track Faculty Members|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Marian Kalocsay|
|Cancer Sites||All Sites|
|Summary of Goals and Objectives||
Cancer therapy directed against repressive immune checkpoints that tumors exploit to escape immune attack has seen enormous success. However, checkpoint receptor signaling is incompletely understood, causing fundamental questions on why effective anti-checkpoint therapy is limited to only a few cases to remain elusive. Illuminating underlying molecular signaling mechanisms - the goal of this project - is required to understand and find new ways to combat tumor evasion. The proposed research will address which proteins participate in checkpoint receptor signaling and reverse ligand signaling. Novel proximity proteomics methods and state-of-the-art mass spectrometry will provide the means to d...